Related Experiment Video

Updated: Jun 2, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Fibroblast growth factor receptor 4 regulates proliferation and antiapoptosis during gastric cancer progression

Yan Wei Ye1, Ye Zhou, Lin Yuan

  • 1Department of Abdominal Surgery, Fu Dan University Shanghai Cancer Center, Shanghai, China.

Cancer
|May 14, 2011
PubMed
Abstract

Insights

High expression of Fibroblast Growth Factor Receptor 4 (FGFR4) in gastric cancer (GC) correlates with poorer prognosis. Inhibiting FGFR4 reduced tumor cell proliferation and increased apoptosis, suggesting FGFR4 as a potential therapeutic target for GC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Fibroblast Growth Factor Receptor 4 (FGFR4) is a tyrosine kinase receptor with largely unknown roles in gastric cancer (GC).
  • Understanding FGFR4's involvement is crucial for advancing GC treatment strategies.

Purpose of the Study:

  • To investigate the role of FGFR4 in the development and progression of gastric cancer.
  • To determine the prognostic significance of FGFR4 expression in GC patients.

Main Methods:

  • Immunohistochemical analysis of FGFR4, p53, neu, and proliferating cell nuclear antigen (PCNA) in 71 GC tissue samples.
  • Functional assays including proliferation, clone formation, and apoptosis detection using small interfering RNA (siRNA) to knockdown FGFR4.
  • Western blot analysis to assess caspase 3 and B-cell lymphoma-extra large (Bcl-xL) expression.

Main Results:

  • High cytoplasmic FGFR4 expression was observed in 38% of GC tissues and associated with lymph node status, PCNA, and neu expression.
  • Patients with high FGFR4 expression showed a trend towards poorer 5-year survival (42% vs. 61.5%), particularly those with stage III/IV disease.
  • FGFR4 knockdown in GC cell lines (MKN45, SGC7901) significantly reduced proliferation and increased apoptosis, with altered caspase 3 and Bcl-xL levels.

Conclusions:

  • FGFR4 is highly expressed in GC and linked to disease progression.
  • FGFR4 appears to promote GC by enhancing proliferation and inhibiting apoptosis.
  • FGFR4 represents a promising novel therapeutic target for gastric cancer treatment.

More Related Videos

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...